Outlook Therapeutics, Inc. — Form 10-Q Summary
Reporting period: Third fiscal quarter and nine months ended June 30, 2021; filed August 13, 2021. The company is a late clinical-stage biopharmaceutical developer focused on ONS-5010, an ophthalmic bevacizumab candidate for retinal diseases.
Financial results and liquidity
| Metric | Three months ended June 30, 2021 | Nine months ended June 30, 2021 |
|---|---|---|
| Revenue | No product sales; revenue value is not separately stated in the provided filing text | No product sales; revenue value is not separately stated in the provided filing text |
| Research and development expense | $8.5 million | $29.0 million |
| General and administrative expense | $2.9 million | $9.3 million |
| Operating loss | $11.5 million | $38.3 million |
| Net loss | $12.2 million | $39.8 million |
| Net loss per share, basic and diluted | $0.07 | $0.27 |
| Cash used in operating activities | Not presented for the quarter | $45.3 million |
At June 30, 2021, cash was $19.7 million, current assets were $31.9 million, current liabilities were $19.6 million, and total liabilities were $20.1 million. Debt, net of loan costs, was $11.5 million, all classified as current: principally a $10.7 million unsecured note due January 1, 2022, plus a $0.9 million PPP loan due in 2022. The company reported no product-sales revenue and has incurred recurring losses and negative operating cash flow; margins are not meaningful for this pre-commercial business.
Changes versus comparable periods
- For the quarter, net loss increased to $12.2 million from $3.0 million. The prior-year quarter included a $6.2 million gain on debt extinguishment and a $3.3 million income tax benefit, while 2021 included a $0.4 million equity-method investment loss.
- For the nine months, net loss rose to $39.8 million from $25.3 million. R&D expense increased $10.3 million, primarily from ONS-5010 clinical development, NORSE THREE, manufacturing scale-up and BLA preparation.
- Cash used in operations increased to $45.3 million from $19.7 million for the nine-month period, including higher development spending and cash tied up in prepaid development costs.
- Cash increased from $12.5 million at September 30, 2020, supported by equity offerings, warrant exercises and new borrowing. Common shares outstanding rose from 127.2 million to 174.8 million over that period.
Outlook, risks and unusual items
- Management stated that June 30 cash plus $1.3 million of net ATM proceeds raised in July was expected to fund operations through December 2021. The company explicitly disclosed substantial doubt about its ability to continue as a going concern and said substantial additional financing is needed; funding plans include equity, debt, licensing, marketing or collaboration arrangements, with no assurance of success.
- The filing describes a planned first-quarter 2022 BLA submission for ONS-5010 in wet AMD. It reports that NORSE ONE and NORSE THREE had positive results; the filing also reports August 2021 NORSE TWO topline results meeting the primary and key secondary efficacy endpoints. Those results occurred after the June 30 reporting date.
- Potential future development includes registration trials for branch retinal vein occlusion and diabetic macular edema. Regulatory approval, trial outcomes, manufacturing readiness, financing, commercial acceptance and competition remain significant uncertainties.
- A Liomont contract dispute was settled and dismissed in April 2021. The company paid $625,000, with another $750,000 contingent on specified future events.
- The PRC joint venture received a royalty-free ONS-5010 license for greater China; Outlook holds a 20% interest and expects approximately $2.1 million of additional capital contributions over four years.
- COVID-19 had caused limited disruption to date, but the company cautioned that future effects on clinical, CMC and regulatory timelines remained uncertain. Management said disclosure controls were effective and reported no material change in internal control over financial reporting.
Important facts for investors to verify
- Whether the company obtained sufficient financing after the stated December 2021 cash runway, and the resulting dilution, debt terms or partnership economics.
- The complete NORSE TWO results and their consistency with the planned BLA filing, including regulatory feedback and manufacturing readiness.
- The timing and amount of the unsecured note repayment and PPP loan obligations.
- Whether the contingent $750,000 Liomont settlement payment becomes due and the timing of the PRC joint venture’s expected additional contributions.
- Reconcile reported cash resources with the $45.3 million nine-month operating cash outflow and the substantial prepaid development balances.